Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(67%)

Phase Distribution

Ph phase_1
2
67%
Ph phase_2
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

terminated267%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_1

A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

NCT04193904
terminatedphase_1

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

NCT03637803
withdrawnphase_2

Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma

NCT05107427

Clinical Trials (3)

Showing 3 of 3 trials
NCT04193904Phase 1

A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

Terminated
NCT03637803Phase 1

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Terminated
NCT05107427Phase 2

Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3